Roles in PharmNovo: Scientific advisor, Chief scientific officer and Director of the board.
Born: 1954.
Education: Professor. Pharmacy graduate with a PhD in Neuropharmacology and worked as an industrial pharmacologist before returning to academic research at the Universities of Texas and Leicester.
Other current appointments: None.
Work experience: 30 years of Academic and Industrial Research. Until August 2015, he was Professor of Pharmacology and former Head of Biomedical Sciences at the University of Nottingham Medical School.
Holdings: 250 000 shares.
Member of:
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read morePharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read moreAs the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more